维普期刊资源整合服务平台（V6.5）

71篇 您的检索式：作者名="van Rhee F"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	HHV-8-negative,idiopathic multicentric Castleman disease:novel insights into biology,pathogenesis,and therapy显示文摘	Fajgenbaum DC van Rhee F Nabel CS	2014	Blood2014，123，19：	1
2	International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols 显示文摘	Waheed S Shaughnessy JD van Rhee F	2011	Cancer2011，117，5：	1
3	NY-ES()-I is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses 显示文摘	van Rhee F Szmania SM Zhan F	2005	Blood2005，105，10：	1
4	High serum free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis显示文摘	van Rhee F Bolejaek V Hollmig K	2007	Blood2007，110，3：	1
5	Sihuximab, a novel anti- interleukin-6 monoclonal antibody, for Castleman's disease 显示文摘	Van Rhee F Fayad L Voorhees P	2010	J Clin Oncol2010，28，23：	1
6	VTD combination therapy with bortezomib-thalidomide- dexamethasone is highly effective in advanced and refractory multiple myeloma 显示文摘	PINEDA-ROMAN M ZANGARI M VAN RHEE F	2008	Leukemia2008，22，7：	1
7	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma显示文摘	BARLOGIE B TRICOT G J van RHEE F	2006	Br J Haematol2006，135，2：	1
8	p190 BCR-ABL mRNA isexpressed at low levels in P210-positive chronic myeloid and acute lymphoblastie leukemias 显示文摘	van Rhee F Hochhaus A Lin F	1996	Blood1996，87，12：	1
9	NY-ESO-1 is highly expressed Jn poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses显示文摘	Van Rhee F Szmania SM Zhan F	2005	Blood2005，105，：	1
10	lnternational staging system and metaphase eytogenetie abnormalities in the era of gene expression profiling dala in multiple myeloma treated with total !htrapy 2 and 3 protocols显示文摘	Waheed S Shaughnessy JD van Rhee F	2011	Cancer2011，117，5：	1
11	Seven-year median time to progression with thalidomide for smoldering myeloma:Partial response identifies subset requiring earlier salvage therapy for symptomatic disease显示文摘	Barlogie B Van Rhee F Shaughnessy JD Jr	2008	Blood2008，112，：	1
12	Adoptive immunotherapy for relapse of chronic myeloid leukemia after al ogeneic bone mar row transplant:equal efficacy of lymphocytes from sibling and matched unrelated donors显示文摘	van Rhee F Savage D Blackwel J		0，，10：	1
13	Thalidomide arm of total therapy 2improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities显示文摘	Barlogie B Pineda-Roman M van Rhee F	2008	Blood2008，112，：	1
14	The future of autologous stem cell transplantation in myeloma显示文摘	van Rhee F Giralt S Baxlogie B1	2014	Blood2014，124，3：	1
15	Eruptivecherry hemangiomatosis associated with multicentric Castle-man disease:a case report and diagnostic clue 显示文摘	Fajgenbaum D Rosenbach M van Rhee F	2013	JAMADermatol2013，149，2：	1
16	Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma显示文摘	van Rhee F Szmania SM Dil on M		0，，09：	1
17	Castleman Disease in the 21st Century: An Update on Diagnosis, Assessment, and Therapy 显示文摘	van Rhee F Stone K Szmania S	2010	Clin Adv Hematol Oncol2010，8，7：	1
18	Superior re- sults of Total Therapy 3 (2003-33) in gene expression profi- ling-defined low-risk multiple myeloma confirmed in subse- quent trial 2006-66 with VRD maintenance显示文摘	Nair B van Rhee F Shaughnessy JD Jr	2010	Blood2010，115，21：	1
19	Lang term results after allogeneic bone marrow transplantation for chronic mye-logenous leukemia in chronic phase:a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation显示文摘	van Rhee F Szydlo RM Hermans J	1997	Bone Marrow Transplant1997，20，7：	1
20	Siltuximab, a no- vel anti interleukin-6 monoclonal antibody, for Castleman's disease 显示文摘	Van Rhee F Fayad L Voorhees P	2010	J Clin Oncol2010，28，23：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示